Barclays views Illumina’s (ILMN) guidance last night as largely as expected. The bulls are going to defend the stock on China being de-risked, ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 49.02% Upside As of ...

In a report released today, Luke Sergott from Barclays maintained a Sell rating on Illumina (ILMN – Research Report), with a price target of ...

Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...

Piper Sandler raised their price target on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Finally, Barclays cut ...

Sergott covers the Healthcare sector, focusing on stocks such as Illumina, Sotera Health, and Agilent. The word on The Street in general, suggests a Hold analyst consensus rating for Illumina with ...